Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication

Tegoprazan, a novel potassium-competitive acid blocker, is currently available for the treatment of Helicobacter pylori infection. We compared the efficacies of tegoprazan-based triple and concomitant therapies in a real-world practice. Data of patients treated with a 14-day tegoprazan-based triple...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Chan Hyuk, Song, Myung Jin, Jung, Byung Wook, Park, Jung Ho, Jung, Yoon Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695183/
https://www.ncbi.nlm.nih.gov/pubmed/36422094
http://dx.doi.org/10.3390/jpm12111918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695183/
https://www.ncbi.nlm.nih.gov/pubmed/36422094
http://dx.doi.org/10.3390/jpm12111918

Ejemplares similares